When you submit a product licence application for a natural health product in Canada, your submission does not enter a single universal queue. Health Canada assigns every application to one of three classes, and that classification determines the evidence standard and the review timeline your product will face. Knowing how NHP Class I, II or III in Canada works before you build your submission package is one of the most practical steps you can take to protect your launch timeline.
The classification system falls under Health Canada’s Natural Health Products Regulations and is governed by the Management of Applications Policy (MAP), most recently updated in December 2025. Your product class depends on whether a published monograph covers it, how closely your formulation aligns with that monograph, and what type of evidence supports your claims. Each class carries a different service standard for review, ranging from 60 days to nearly a year. That difference has real consequences for your go-to-market planning. Keep reading to learn more.
What Determines an Application’s Class?
Health Canada classifies NHP applications based on the complexity of the evidence supporting your product’s safety, efficacy, and quality claims. The central question is always the same: does a Health Canada monograph exist for this product, and does your formulation comply fully with its parameters?
A monograph is a pre-assessed standard published by the Natural and Non-prescription Health Products Directorate (NNHPD). When your product meets all monograph criteria, including ingredient source, dose, duration of use, and recommended purpose, Health Canada treats your submission as lower risk. The more your product deviates from a published monograph, the more independent supporting evidence you need. That is what moves an application from Class I toward Class III.
Class I: Single-Monograph Compendial Applications
A Class I NHP application in Canada is a compendial submission. Your product meets all the parameters of a single Health Canada monograph and makes no claims beyond what that monograph permits. Health Canada validates these applications against the monograph data in real time through the web-based Product Licence Application (web PLA) form.
Because Class I involves no independent evidence review, it carries Health Canada’s shortest service standard: 60 days. For companies with a product that maps cleanly to a published monograph, this is the most efficient licensing pathway. However, even a minor deviation from monograph parameters will move your application out of Class I immediately.
Class II: Multi-Monograph or Minor Deviation Applications
A Class II NHP application in Canada applies to products that still rely on monograph-based evidence but do not fit within a single monograph. Your product might combine ingredients from two separate monographs, or it might use traditional use evidence alongside monograph support. Class II also covers products that follow a monograph for most parameters but require a small additional evidence component.
Health Canada’s service standard for Class II is 90 days. That additional 30 days reflects the added complexity of cross-referencing multiple compendial sources. Mischaracterizing a Class II product as Class I is one of the most common causes of a screening rejection, so accurately identifying your application type before submission matters.
Class III: Non-Compendial Applications Requiring Independent Evidence
Class III NHP applications in Canada apply when your product cannot be supported by any published monograph. Your submission requires independent clinical evidence, published studies, systematic reviews, or a well-documented traditional use history with supporting literature.
Class III products typically include new ingredient combinations, novel dosage forms, higher-than-monograph doses, or claims Health Canada has not previously assessed. The service standard is 300 days. For companies developing innovative formulations or entering Canada without a direct monograph equivalent, this means your regulatory strategy and evidence package need to be in motion well before your target launch date.
Quality Smart Solutions works with companies at all three classification levels, helping teams confirm where a product is likely to land and how to structure the submission from the start. You can explore the full scope of NHP licensing support at Quality Smart Solutions to understand what that looks like in practice.
A Quick Reference: The Three NHP Application Classes
- Class I: Single monograph, fully compliant. 60-day service standard.
- Class II: Multiple monographs or minor deviation. 90-day service standard.
- Class III: Non-compendial, independent evidence required. 300-day service standard.
What Happens if Your Product Is Misclassified?
If Health Canada screens your submission and determines it was filed under the wrong class, your application can be returned. That means restarting the process and potentially missing a retail window or customer commitment. For products near the boundary between classes, a careful pre-submission review is the most effective way to avoid that outcome. Health Canada’s Natural Health Product Licence Application Form User Guide outlines the full classification criteria and submission requirements for each class.
Frequently Asked Questions
Can a single product have ingredients that fall under different classes?
The application class is assigned to the product as a whole, not to individual ingredients. If most of your formula is covered by a monograph but one ingredient requires independent evidence, Health Canada will classify the entire submission based on the highest level of evidence needed. A single unresolved ingredient can move a Class I or Class II application into Class III territory. Reviewing every ingredient against the Natural Health Products Ingredients Database (NHPID) before submission is essential.
Does a Class III application mean my product is at higher risk?
Not necessarily. Class III reflects the type of evidence required, not a judgement about the product’s safety. The designation means Health Canada has not previously assessed this type of product against a published standard, so it conducts a full independent review. A well-organized submission with complete supporting literature is the most effective way to move through the 300-day review window without unnecessary delays.
If my product was approved in the United States, does that affect my NHP class in Canada?
No. Health Canada evaluates NHP applications entirely independent of FDA decisions. A U.S. dietary supplement approval, GRAS status, or NDI notification carries no weight in the NHP classification process. Products often require significantly different evidence packages for the Canadian market, and companies that assume otherwise have faced costly gaps in their submissions.
Key Takeaways
- NHP applications in Canada fall into three classes, each with a different evidence standard and review timeline.
- Class I is fully monograph-compliant with a 60-day service standard; Class II involves multiple monographs or minor deviations at 90 days; Class III requires independent evidence at 300 days.
- Misclassifying an application can result in a screening rejection and significant delays.
- Class III does not signal a problem with your product. It signals the need for a stronger, earlier-stage regulatory strategy.
- Pre-submission class assessment is a high-value step that protects your timeline and your submission investment.
Getting Your Classification Right Before You Submit
Choosing the correct application class is a foundational decision in your Canadian market entry strategy. Quality Smart Solutions has guided companies through all three NHP application classification types since 2007, across products ranging from single-ingredient supplements to complex multi-ingredient formulations.
If you are preparing a product licence application and want to confirm the right pathway before building your evidence package, contact our regulatory experts to start the conversation.
